GlassScriptPhysician profile
Tracy Lee Pride
NPI 1548375934
$7,096.02
in general payments reported to CMS, 2019-2025
26 companies · $787 in 2025
The $787 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $833 · 2022: $1,450 · 2023: $3,062 · 2024: $965 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,251 · Travel and Lodging: $1,518 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.09 |
| Travel and Lodging | $1,517.84 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,715.64 | 2021-2025 | Advisa Dr Mri Surescan, Micra, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $530.08 | 2021-2025 | Lifevest |
| Pfizer INC. | $414.41 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $305.61 | 2022-2025 | Optimizer |
| Janssen Pharmaceuticals, INC | $248.14 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $247.22 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $228.64 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $225.84 | 2021-2023 | Jot Dx |
| Boston Scientific Corporation | $168.93 | 2021-2025 | Watchman Flx, Watchman |
| Astrazeneca Pharmaceuticals LP | $134.08 | 2023-2025 | Brilinta, Wainua, Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.47 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $111.42 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $107.13 | 2021-2025 | |
| Edwards Lifesciences Corporation | $96.64 | 2021 | |
| Angiodynamics, INC. | $86.96 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $79.66 | 2023 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $70.12 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $45.54 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $21.83 | 2022 | |
| Atricure, INC. | $20.89 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $20.56 | 2023 | Arcalyst |
| Siemens Medical Solutions USA, INC. | $19.06 | 2023 | Corpath Imaging System |
| Abiomed | $18.37 | 2023 | Impella |
| Biotronik INC. | $17.47 | 2025 | Acticor 7 Vr-T Dx |
| Rigel Pharmaceuticals, INC. | $15.42 | 2024 | Tavalisse, Rezlidhia |
| Livanova USA, INC. | $14.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Pride listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.